Factor VIII

Generic Medicine Info
Indications and Dosage
Treatment and prophylaxis of haemorrhagic episodes in patients with haemophilia A
Adult: Dosage is individualised based on coagulation tests performed before treatment and at regular intervals during treatment. Generally, 1 IU/kg will increase circulating factor VIII levels by about 2 IU/dL. Recommended doses vary according to the preparation used. Suggested doses: Mild-moderate haemorrhage (increase to 20-30% of normal): Usually with a single dose of 10-15 units/kg; more serious haemorrhage or minor surgery (increase to 30-50% of normal): Usual initial dose of 15-25 units/kg followed by 10-15 units/kg every 8-12 hr if required; severe haemorrhage or major surgery (increase to 80-100% of normal): Usual initial dose of 40-50 units/kg followed by 20-25 units/kg every 8-12 hr. Refer to individual product information for further dosing details.

Prophylaxis in severe haemophilia A
Adult: 10-50 u/kg every 2-3 days, as needed.
Treatment and prophylaxis of haemorrhagic episodes...: If refrigerated, warm dried concentrate and diluent to room temperature before reconstitution.
Special Precautions
Risk of intravascular haemolysis in patients with blood groups A, B, or AB receiving high doses or repeated doses of factor VIII preparations. Risk of transmission of some viral infections especially hepatitis B and C. Dose requirement may vary in patients with factor VIII inhibitors; thus optimal treatment should be based on clinical response. Monitor platelet counts regularly during treatment. Pregnancy, lactation.
Adverse Reactions
Allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion.
IV/Parenteral: C
Description: Factor VIII is required for clot formation and maintenance of haemostasis. It activates factor X in conjunction with activated factor IX. Activated factor X then converts prothrombin to thrombin, which converts fibrinogen to fibrin, and forms a stable clot with factor XIII. Factor VIII is used for replacement therapy in patients with haemophilia A.
Excretion: Terminal half-life of about 12 hr.
Treatment and prophylaxis of haemorrhagic episodes...: Store between 2-8°C. Use within 3 hr of reconstitution; do not refrigerate after reconstitution due to risk of precipitation.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Factor VIII from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
  • Biostate
  • Fanhdi
  • Haemoctin SDH 250
  • Kogenate FS
  • Optivate
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in